Astragalus Membranaceus Improving Asymptomatic Left Ventricular Diastolic Dysfunction in Postmenopausal Hypertensive Women with Metabolic Syndrome： A Prospective, Open-Labeled, Randomized Controlled Trial  

作　　者：Ning-Yin Li Heng Yu Xiu-Li Li Qiong-Ying Wang Xiao-Wei Zhang Rui-Xin Ma Yang Zhao Han Xu Wei Liang Feng Bai Jing Yu 

机构地区：[1]Department of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, Gansu 730000, China

出　　处：《Chinese Medical Journal》2018年第5期516-526,共11页中华医学杂志（英文版）

摘　　要：Background： Postmenopausal women with metabolic syndrome （MetS） have increased cardiovascular morbidity and left ventricular diastolic dysfunction （LVDD）. The various protective effects ofastragalus membranaceus （AM） have been described in previous studies. Therefore, this study aimed to evaluate the effects of different doses of AM on diastolic function in postmenopausal hypertensive women with MetS. Methods： This was a prospective, randomized controlled study. The postmenopausal hypertensive patients with MetS were enrolled from Lanzhou University Second Hospital from March 2014 to April 2015. Patients were divided into three groups： control group （received conventional medical treatment）, AM Group 1 （received AM capsules at 5 g/d additionally）, and AM Group 2 （received AM capsules at 10 g/d additionally）. Echocardiographic and clinical characteristics were evaluated before and 12 months after treatment. Quantitative data were analyzed using unpaired t-test, analysis of variance, and multiple linear regression analysis. Results： A total of 154 patients were subjected to final analysis. In the AM Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity （E＇; 0.065±0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014）, the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity （E/A; 0.81± 0.05 vs. 0.80± 0.06, P = 0.012）, the ratio of E＇ to the late diastolic mitral annular velocity （EVA＇; 0.56 ± 0.12 vs. 0.51 ± 0.13, P 0.048）, and the ratio of the early diastolic mitral peak flow velocity （E） to E＇ （E/E＇; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031）. After treatment, E/E＇ （ 10.70 ± 1.30 vs. 11.24± 1.56, P = 0.021 ）, deceleration time （DT; 261.49 ± 44.41 ms vs. 268.74 ±53.87 ms P = 0.046）, and EVA＇ （0.56 ± 0.12 vs. 0.52 ±0.13, P = 0.019） values improved more significantBackground： Postmenopausal women with metabolic syndrome （MetS） have increased cardiovascular morbidity and left ventricular diastolic dysfunction （LVDD）. The various protective effects ofastragalus membranaceus （AM） have been described in previous studies. Therefore, this study aimed to evaluate the effects of different doses of AM on diastolic function in postmenopausal hypertensive women with MetS. Methods： This was a prospective, randomized controlled study. The postmenopausal hypertensive patients with MetS were enrolled from Lanzhou University Second Hospital from March 2014 to April 2015. Patients were divided into three groups： control group （received conventional medical treatment）, AM Group 1 （received AM capsules at 5 g/d additionally）, and AM Group 2 （received AM capsules at 10 g/d additionally）. Echocardiographic and clinical characteristics were evaluated before and 12 months after treatment. Quantitative data were analyzed using unpaired t-test, analysis of variance, and multiple linear regression analysis. Results： A total of 154 patients were subjected to final analysis. In the AM Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity （E＇; 0.065±0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014）, the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity （E/A; 0.81± 0.05 vs. 0.80± 0.06, P = 0.012）, the ratio of E＇ to the late diastolic mitral annular velocity （EVA＇; 0.56 ± 0.12 vs. 0.51 ± 0.13, P 0.048）, and the ratio of the early diastolic mitral peak flow velocity （E） to E＇ （E/E＇; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031）. After treatment, E/E＇ （ 10.70 ± 1.30 vs. 11.24± 1.56, P = 0.021 ）, deceleration time （DT; 261.49 ± 44.41 ms vs. 268.74 ±53.87 ms P = 0.046）, and EVA＇ （0.56 ± 0.12 vs. 0.52 ±0.13, P = 0.019） values improved more significant

关 键 词：Astragalus Membranaceus Hypertension Left Ventricular Dysfunction Metabolic Syndrome POSTMENOPAUSE 

分 类 号：S858.292[农业科学—临床兽医学] TS974.1[农业科学—兽医学]